To this regard, LB using as substrate the cell-free tumor DNA (ctDNA) has provided considerable application in tracking the RAS mutational (RASmut) status, in order to refine the use of anti-EGFR mAbs in CRC, while a limited experience exists to date regarding either CTCs or EVs. This evidence concerns the gene EGFR and colorectal carcinoma.